GoodRx Holdings, Inc. Earnings Recaps
Q2 2026
Aug 8, 2026
Shares rallied 12.5% following GoodRx’s Q2 report, driven by better-than-expected revenue growth—most notably a 76% year-over-year surge in Pharma Direct revenue—and an upgraded full-year outlook reflecting increased confidence in returning to year-over-year growth sooner than anticipated.
Key takeaways
- Pharma Direct revenue accelerated 76% year-over-year and 18% quarter-over-quarter, led by expanded consumer direct pricing programs including major brands like Jardiance and Otezla.
- GLP-1 medication demand remains robust, with GoodRx supporting several new launches, solidifying its role as a key consumer access channel in this high-growth segment.
- Subscription initiatives, including the recent launch of GoodRx Companion, are becoming increasingly central to customer retention and engagement strategies.
- Management raised full-year revenue and adjusted EBITDA guidance based on strong Q2 trends, signaling confidence in sustaining growth momentum.
- Leadership change: previously Chief Strategy and Operations Officer Justin Fengler appointed CFO, ensuring continuity in financial leadership amid the company’s strategic evolution.
Q1 2026
May 10, 2026
GoodRx shares edged up 2.8% post-earnings, reflecting a generally steady reaction to solid growth in Pharma Direct and broader platform engagement but without a clear breakout catalyst to push the stock higher.
Key takeaways
- Pharma Direct revenue surged 82% year-over-year, fueled by manufacturer-sponsored pricing programs and strong uptake of new GLP-1 therapies such as Wegovy Pill and Ozempic Pill.
- GoodRx accounted for roughly one-third of Wegovy Pill transactions in the first two months post-launch, underscoring its growing influence in the self-pay prescription market.
- The company expanded manufacturer collaborations, including a new program with Viatris for 17 brand medications and a Pfizer-branded storefront offering discounts on 30+ essential drugs.
- Rx Marketplace performance aligned with internal expectations, supported by ongoing e-commerce expansion and direct contracting models.
- Management highlighted evolving healthcare dynamics—widening coverage gaps and elevated out-of-pocket costs—that continue to validate GoodRx’s strategy of improving affordability and access.
Q3 2025
Nov 6, 2025
GoodRx delivered solid third-quarter performance with a 54% year-over-year revenue growth in its Manufacturer Solutions segment, despite facing challenges from the completion of Rite Aid store closures.
Key takeaways
- Strong execution led to 54% revenue growth in the Manufacturer Solutions segment, highlighting GoodRx’s effectiveness in improving patient access and affordability.
- Expanded partnerships with manufacturers like Novo Nordisk and Amgen, enhancing the company's cash pricing offerings for key medications.
- Launched new initiatives such as the RxSmartSaver counter solution with Kroger and the Savings Wrangler campaign to strengthen consumer brand trust.
- Ongoing navigation of industry headwinds, particularly from Rite Aid closures, but strategies to recapture displaced users are in progress.
- The evolving U.S. healthcare landscape presents a favorable opportunity for GoodRx, aligning with shifts towards transparency and affordability in drug pricing.